Every 10-Q that Medtronic plc (MDT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDT filings page.
Medtronic plc (MDT) reported a strong first quarter of fiscal 2027, with net sales of $9.76 billion for the three months ended July 31, 2026, up from $8.58 billion a year earlier. Net income attributable to Medtronic rose to $1.47 billion from $1.04 billion, and diluted EPS increased to $1.14 from $0.81.
Growth was broad-based: Cardiovascular revenue reached $3.93 billion, Neuroscience $2.68 billion, Medical Surgical $2.28 billion, and Diabetes $0.84 billion, all above prior-year levels. Operating cash flow strengthened to $1.79 billion. Medtronic closed two Neuroscience acquisitions, Scientia Vascular and SPR Therapeutics, with purchase prices of $681 million and $654 million, adding technology-based and customer-related intangibles and increasing goodwill. The company ended the quarter with $1.69 billion in cash and $7.15 billion in available-for-sale debt securities, against $2.54 billion of current debt and $25.62 billion of long-term debt. Medtronic also detailed ongoing legal, environmental, and tax matters, including recent jury verdicts, and stated that related ultimate outcomes and losses remain uncertain.
Medtronic plc reported fiscal Q3 2026 net sales of $9.0 billion, up from $8.3 billion a year earlier, driven by growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Operating profit declined to $1.5 billion, and net income attributable to Medtronic fell to $1.1 billion, with diluted EPS at $0.89 versus $1.01.
For the first nine months, revenue reached $26.6 billion, up from $24.6 billion, while net income was roughly flat at $3.6 billion and diluted EPS was $2.76. Strong operating cash flow of $4.8 billion funded $2.7 billion in dividends and $0.6 billion of share repurchases, even as long‑term debt rose to $27.9 billion.
The company is preparing to separate its Diabetes business into MiniMed, an independent public company, and has launched a restructuring program expected to cost $300–$500 million through fiscal 2029. Medtronic also recorded higher restructuring and certain litigation charges and continued using derivative and funding arrangements to manage currency, interest rate, and development risks.
Medtronic plc reported higher results for the quarter ended October 24, 2025. Net sales rose to $8,961 million from $8,403 million a year earlier, driven by growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, with segment sales reaching $8,926 million. Net income attributable to Medtronic increased to $1,374 million from $1,270 million, and diluted earnings per share improved to $1.07 from $0.99.
For the first six months of fiscal 2026, net sales were $17,539 million versus $16,318 million, and net income attributable to Medtronic was $2,414 million compared with $2,312 million. Operating cash flow was $2,013 million, while the company continued returning cash via dividends of $1,820 million and share repurchases of $495 million. Medtronic reduced its Italian payback accrual by $39 million, recorded as a sales benefit, and recognized a $90 million fair value loss on its Mozarc Medical investment.
On the balance sheet, cash and cash equivalents stood at $1,282 million with $7,045 million in investments. Total assets were $91,346 million, total liabilities $42,489 million, and total equity $48,857 million. Long-term debt increased to $27,680 million, including new 2.950% notes due 2031 and 4.200% notes due 2046, and the company had $1.4 billion of commercial paper outstanding.
Medtronic (MDT) reported first-quarter fiscal 2026 operating details showing continued product-driven revenue growth across core portfolios and ongoing corporate actions. The company announced in May 2025 its intent to separate the Diabetes Operating Unit into a standalone public company, expected within 18 months. Cardiovascular net sales were up, with Cardiac Rhythm & Heart Failure rising 12%, Structural Heart & Aortic up 9%, and Coronary & Peripheral Vascular up 5%. Medical Surgical net sales were $2.1 billion, up 4% year-over-year. Research and development expense was $726 million versus $676 million a year earlier, and selling, general, and administrative expense was $2.8 billion versus $2.7 billion. The company recognized a $90 million fair-value loss on its Mozarc investment and recorded restructuring charges of $67 million. Deferred revenue was $442 million. Total debt was $28.6 billion while liquidity included $1.3 billion cash and $6.8 billion of current investments. Accrued litigation was approximately $0.2 billion; legal and tax matters remain disclosed as potentially material.